Multisystem inflammatory syndrome associated with COVID-19 in pediatric patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | spa |
Título da fonte: | Sapienza (Curitiba) |
Texto Completo: | https://journals.sapienzaeditorial.com/index.php/SIJIS/article/view/306 |
Resumo: | Pediatric Multisystem Inflammatory Syndrome (P-MIS) linked to SARS-CoV-2 is a generalized inflammatory reaction that develops approximately 4-6 weeks after COVID-19 illness. The aim of the article was to analyze the immunopathogenesis, diagnosis and treatment of P-MIS. A systematic literature review was performed using databases such as Embase, Redalyc, LILACS, SciELO, Springer, Elsevier, EBSCO and Google Scholar and the keywords: Coronavirus disease, Kawasaki disease, child, intravenous immunoglobulins. Inclusion criteria were: full articles, published between the years 2019-2022, in English and Spanish. Of the 273 articles found, 243 articles were rejected for not meeting the established criteria, with 30 articles selected as eligible. According to the results, SIM-P is characterized by fever, myocardial injury, shock and development of coronary artery aneurysms; laboratory tests show: elevation of markers of inflammation, changes in coagulation tests, especially significant elevation of D-dimer and fibrinogen and elevation of markers of myocardial injury, troponin and natriuretic peptide. Phase 1 treatment occurs with the administration of intravenous immunoglobulin G (IVIG), corticosteroids, low molecular weight heparin in a prophylactic dose; in phase 2, treatment consists of administration of a second dose of IVIG, progressive reduction of prednisone and use of biological therapy; and, in phase 3, infliximab or tocilizumab is used. In conclusion, SIM-P has elevated inflammatory markers and multi-organ involvement, with no associated bacterial diagnosis, with evidence of infection or recent exposure to SARS-CoV-2. |
id |
SAPIENZA_87918f9352a2e82feac4c6c0b6d6d626 |
---|---|
oai_identifier_str |
oai:ojs2.journals.sapienzaeditorial.com:article/306 |
network_acronym_str |
SAPIENZA |
network_name_str |
Sapienza (Curitiba) |
repository_id_str |
|
spelling |
Multisystem inflammatory syndrome associated with COVID-19 in pediatric patientsSíndrome inflamatorio multisistémico asociado a COVID-19 en pacientes pediátricosSíndrome inflamatória multissistêmica associada à COVID-19 em pacientes pediátricosDoença de coronavírus 2019-nCoV; Doença de Kawasaki; crianças; imunoglobulinas intravenosasCoronavirus disease 2019-nCoV; Kawasaki disease; little boy; intravenous immunoglobulinsenfermedad por Coronavirus 2019-nCoV; enfermedad de Kawasaki; niño; inmunoglobulinas intravenosasPediatric Multisystem Inflammatory Syndrome (P-MIS) linked to SARS-CoV-2 is a generalized inflammatory reaction that develops approximately 4-6 weeks after COVID-19 illness. The aim of the article was to analyze the immunopathogenesis, diagnosis and treatment of P-MIS. A systematic literature review was performed using databases such as Embase, Redalyc, LILACS, SciELO, Springer, Elsevier, EBSCO and Google Scholar and the keywords: Coronavirus disease, Kawasaki disease, child, intravenous immunoglobulins. Inclusion criteria were: full articles, published between the years 2019-2022, in English and Spanish. Of the 273 articles found, 243 articles were rejected for not meeting the established criteria, with 30 articles selected as eligible. According to the results, SIM-P is characterized by fever, myocardial injury, shock and development of coronary artery aneurysms; laboratory tests show: elevation of markers of inflammation, changes in coagulation tests, especially significant elevation of D-dimer and fibrinogen and elevation of markers of myocardial injury, troponin and natriuretic peptide. Phase 1 treatment occurs with the administration of intravenous immunoglobulin G (IVIG), corticosteroids, low molecular weight heparin in a prophylactic dose; in phase 2, treatment consists of administration of a second dose of IVIG, progressive reduction of prednisone and use of biological therapy; and, in phase 3, infliximab or tocilizumab is used. In conclusion, SIM-P has elevated inflammatory markers and multi-organ involvement, with no associated bacterial diagnosis, with evidence of infection or recent exposure to SARS-CoV-2.El Síndrome inflamatorio multisistémico pediátrico (SIM-P) vinculado a SARS-CoV-2 es una reacción inflamatoria generalizada desarrollada aproximadamente 4-6 semanas después de haber presentado la enfermedad COVID-19. El objetivo del artículo fue analizar la inmunopatogénesis, diagnóstico y tratamiento del SIM-P. Se aplicó un diseño documental, con revisión de bibliografías en bases de datos como Embase, Redalyc, LILACS, SciELO, Springer, Elsevier, EBSCO y Google Académico, utilizando los descriptores: enfermedad por Coronavirus, enfermedad de Kawasaki, niño, inmunoglobulinas intravenosas. Los criterios de inclusión fueron: artículos completos, publicados entre los años 2019-2022, en idiomas inglés y español. Se incluyó la revisión de 273 artículos en total rechazando 243 artículos por no contener la información a razón de búsqueda, seleccionados 30 artículos al cumplir con los criterios de elegibilidad. En los resultados SIM-P se caracteriza por fiebre, lesión miocárdica, shock y desarrollo de aneurismas de las arterias coronarias, en las pruebas de laboratorios: elevación de los marcadores de inflamación, alteraciones en las pruebas de coagulación, especialmente elevación significativa del dímero D y fibrinógeno, ascenso de los marcadores de lesión miocárdica de troponina y péptido natriurético. El tratamiento en la fase1 con la administración de inmunoglobulina G intravenosa (IGIV), corticoides, heparina de bajo peso molecular en dosis profiláctica, fase 2 una segunda dosis de IGIV y un descenso progresivo de prednisona y fase 3 utilización de terapia biológica con infliximab o tocilizumab. En las conclusiones SIM-P presenta elevación de marcadores inflamatorios, compromiso de múltiples órganos sin diagnósticos bacterianos asociados, con evidencia de infección o exposición reciente a SARS-CoV-2. A Síndrome Inflamatória Multissistêmica Pediátrica (P-MIS) ligada ao SARS-CoV-2 é uma reação inflamatória generalizada que se desenvolve em, aproximadamente, 4-6 semanas após a doença COVID-19. O objetivo do artigo foi analisar a imunopatogenia, o diagnóstico e tratamento do SIM-P. Uma revisão sistemática da literatura foi realizada, utilizando-se bases de dados como Embase, Redalyc, LILACS, SciELO, Springer, Elsevier, EBSCO e Google Scholar e os descritores: Coronavirus disease, Kawasaki disease, child, intravenous immunoglobulins. Os critérios de inclusão foram: artigos completos, publicados entre os anos de 2019-2022, em inglês e espanhol. Do montante de 273 artigos encontrados, 243 artigos foram rejeitados por não se enquadrarem nos critérios estabelecidos, sendo 30 artigos selecionados como elegíveis. De acordo com os resultados, a SIM-P caracteriza-se por febre, lesão miocárdica, choque e desenvolvimento de aneurismas de artéria coronária; em exames laboratoriais, observam-se: elevação dos marcadores de inflamação, alterações nos testes de coagulação, especialmente elevação significativa do dímero D e fibrinogênio e elevação dos marcadores da lesão miocárdica, troponina e peptídeo natriurético. O tratamento na fase 1 ocorre com a administração de imunoglobulina G intravenosa (IGIV), corticosteróides, heparina de baixo peso molecular em dose profilática; na fase 2, o tratamento consiste na administração de uma segunda dose de IGIV, diminuição progressiva da prednisona e uso de terapia biológica; e, na fase 3, utiliza-se infliximabe ou tocilizumabe. Em conclusão, a SIM-P apresenta marcadores inflamatórios elevados e envolvimento de múltiplos órgãos, sem diagnóstico bacteriano associado, com evidência de infecção ou exposição recente ao SARS-CoV-2.Sapienza Grupo Editorial2022-04-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://journals.sapienzaeditorial.com/index.php/SIJIS/article/view/30610.51798/sijis.v3i2.306Sapienza: International Journal of Interdisciplinary Studies; Vol. 3 No. 2 (2022): Multidisciplinary Contributions; 38-56Sapienza: International Journal of Interdisciplinary Studies; Vol. 3 Núm. 2 (2022): Aportes Multidisciplinarios; 38-56Sapienza: International Journal of Interdisciplinary Studies; v. 3 n. 2 (2022): Contribuições Multidisciplinares; 38-562675-978010.51798/sijis.v3i2reponame:Sapienza (Curitiba)instname:Sapienza Grupo Editorialinstacron:SAPIENZAspahttps://journals.sapienzaeditorial.com/index.php/SIJIS/article/view/306/181Copyright (c) 2022 Gerardo Fernández, Josué Acostahttps://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessFernández, Gerardo Acosta, Josué2022-12-26T21:19:06Zoai:ojs2.journals.sapienzaeditorial.com:article/306Revistahttps://journals.sapienzaeditorial.com/index.php/SIJISPRIhttps://journals.sapienzaeditorial.com/index.php/SIJIS/oaieditor@sapienzaeditorial.com2675-97802675-9780opendoar:2023-01-12T16:42:55.330909Sapienza (Curitiba) - Sapienza Grupo Editorialfalse |
dc.title.none.fl_str_mv |
Multisystem inflammatory syndrome associated with COVID-19 in pediatric patients Síndrome inflamatorio multisistémico asociado a COVID-19 en pacientes pediátricos Síndrome inflamatória multissistêmica associada à COVID-19 em pacientes pediátricos |
title |
Multisystem inflammatory syndrome associated with COVID-19 in pediatric patients |
spellingShingle |
Multisystem inflammatory syndrome associated with COVID-19 in pediatric patients Fernández, Gerardo Doença de coronavírus 2019-nCoV; Doença de Kawasaki; crianças; imunoglobulinas intravenosas Coronavirus disease 2019-nCoV; Kawasaki disease; little boy; intravenous immunoglobulins enfermedad por Coronavirus 2019-nCoV; enfermedad de Kawasaki; niño; inmunoglobulinas intravenosas |
title_short |
Multisystem inflammatory syndrome associated with COVID-19 in pediatric patients |
title_full |
Multisystem inflammatory syndrome associated with COVID-19 in pediatric patients |
title_fullStr |
Multisystem inflammatory syndrome associated with COVID-19 in pediatric patients |
title_full_unstemmed |
Multisystem inflammatory syndrome associated with COVID-19 in pediatric patients |
title_sort |
Multisystem inflammatory syndrome associated with COVID-19 in pediatric patients |
author |
Fernández, Gerardo |
author_facet |
Fernández, Gerardo Acosta, Josué |
author_role |
author |
author2 |
Acosta, Josué |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Fernández, Gerardo Acosta, Josué |
dc.subject.por.fl_str_mv |
Doença de coronavírus 2019-nCoV; Doença de Kawasaki; crianças; imunoglobulinas intravenosas Coronavirus disease 2019-nCoV; Kawasaki disease; little boy; intravenous immunoglobulins enfermedad por Coronavirus 2019-nCoV; enfermedad de Kawasaki; niño; inmunoglobulinas intravenosas |
topic |
Doença de coronavírus 2019-nCoV; Doença de Kawasaki; crianças; imunoglobulinas intravenosas Coronavirus disease 2019-nCoV; Kawasaki disease; little boy; intravenous immunoglobulins enfermedad por Coronavirus 2019-nCoV; enfermedad de Kawasaki; niño; inmunoglobulinas intravenosas |
description |
Pediatric Multisystem Inflammatory Syndrome (P-MIS) linked to SARS-CoV-2 is a generalized inflammatory reaction that develops approximately 4-6 weeks after COVID-19 illness. The aim of the article was to analyze the immunopathogenesis, diagnosis and treatment of P-MIS. A systematic literature review was performed using databases such as Embase, Redalyc, LILACS, SciELO, Springer, Elsevier, EBSCO and Google Scholar and the keywords: Coronavirus disease, Kawasaki disease, child, intravenous immunoglobulins. Inclusion criteria were: full articles, published between the years 2019-2022, in English and Spanish. Of the 273 articles found, 243 articles were rejected for not meeting the established criteria, with 30 articles selected as eligible. According to the results, SIM-P is characterized by fever, myocardial injury, shock and development of coronary artery aneurysms; laboratory tests show: elevation of markers of inflammation, changes in coagulation tests, especially significant elevation of D-dimer and fibrinogen and elevation of markers of myocardial injury, troponin and natriuretic peptide. Phase 1 treatment occurs with the administration of intravenous immunoglobulin G (IVIG), corticosteroids, low molecular weight heparin in a prophylactic dose; in phase 2, treatment consists of administration of a second dose of IVIG, progressive reduction of prednisone and use of biological therapy; and, in phase 3, infliximab or tocilizumab is used. In conclusion, SIM-P has elevated inflammatory markers and multi-organ involvement, with no associated bacterial diagnosis, with evidence of infection or recent exposure to SARS-CoV-2. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-04-30 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://journals.sapienzaeditorial.com/index.php/SIJIS/article/view/306 10.51798/sijis.v3i2.306 |
url |
https://journals.sapienzaeditorial.com/index.php/SIJIS/article/view/306 |
identifier_str_mv |
10.51798/sijis.v3i2.306 |
dc.language.iso.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://journals.sapienzaeditorial.com/index.php/SIJIS/article/view/306/181 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2022 Gerardo Fernández, Josué Acosta https://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2022 Gerardo Fernández, Josué Acosta https://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sapienza Grupo Editorial |
publisher.none.fl_str_mv |
Sapienza Grupo Editorial |
dc.source.none.fl_str_mv |
Sapienza: International Journal of Interdisciplinary Studies; Vol. 3 No. 2 (2022): Multidisciplinary Contributions; 38-56 Sapienza: International Journal of Interdisciplinary Studies; Vol. 3 Núm. 2 (2022): Aportes Multidisciplinarios; 38-56 Sapienza: International Journal of Interdisciplinary Studies; v. 3 n. 2 (2022): Contribuições Multidisciplinares; 38-56 2675-9780 10.51798/sijis.v3i2 reponame:Sapienza (Curitiba) instname:Sapienza Grupo Editorial instacron:SAPIENZA |
instname_str |
Sapienza Grupo Editorial |
instacron_str |
SAPIENZA |
institution |
SAPIENZA |
reponame_str |
Sapienza (Curitiba) |
collection |
Sapienza (Curitiba) |
repository.name.fl_str_mv |
Sapienza (Curitiba) - Sapienza Grupo Editorial |
repository.mail.fl_str_mv |
editor@sapienzaeditorial.com |
_version_ |
1797051607865622528 |